{"id":"medroxyprogesterone","rwe":[{"pmid":"41881051","year":"2026","title":"Idiopathic Intracranial Hypertension Prevalence and Hormonal Contraception: A Meta-Analysis.","finding":"","journal":"Neurology","studyType":"Clinical Study"},{"pmid":"41874764","year":"2026","title":"Effects of human chorionic gonadotropin on echotextural attributes of the original corpus luteum in Morada Nova ewes.","finding":"","journal":"Tropical animal health and production","studyType":"Clinical Study"},{"pmid":"41856890","year":"2026","title":"Use of the injectable contraceptive medroxyprogesterone acetate in France in 2010-2023: A national descriptive study.","finding":"","journal":"Therapie","studyType":"Clinical Study"},{"pmid":"41855532","year":"2026","title":"Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis.","finding":"","journal":"Obstetrics and gynecology","studyType":"Clinical Study"},{"pmid":"41825096","year":"2026","title":"Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis.","finding":"","journal":"Gynecologic oncology","studyType":"Clinical Study"}],"tags":[{"label":"Progestin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Progesterone receptor","category":"target"},{"label":"PGR","category":"gene"},{"label":"AR","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"G03AA08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Subcutaneous","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Atrophic vaginitis","category":"indication"},{"label":"Contraception","category":"indication"},{"label":"Dysfunctional uterine bleeding","category":"indication"},{"label":"Endometrial Hyperplasia Prevention","category":"indication"},{"label":"Endometrial carcinoma","category":"indication"},{"label":"Endometriosis","category":"indication"},{"label":"Pfizer","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Contraceptive Agents","category":"pharmacology"},{"label":"Contraceptive Agents, Female","category":"pharmacology"},{"label":"Contraceptive Agents, Hormonal","category":"pharmacology"},{"label":"Contraceptive Agents, Male","category":"pharmacology"},{"label":"Contraceptives, Oral, Hormonal","category":"pharmacology"},{"label":"Contraceptives, Oral, Synthetic","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":2153.127,"date":"","count":495,"signal":"Unintended pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 495 times (LLR=2153)"},{"llr":769.703,"date":"","count":116,"signal":"Pregnancy with injectable contraceptive","source":"DrugCentral FAERS","actionTaken":"Reported 116 times (LLR=770)"},{"llr":709.146,"date":"","count":215,"signal":"Drug dose omission by device","source":"DrugCentral FAERS","actionTaken":"Reported 215 times (LLR=709)"},{"llr":579.857,"date":"","count":178,"signal":"Incorrect dose administered by device","source":"DrugCentral FAERS","actionTaken":"Reported 178 times (LLR=580)"},{"llr":514.308,"date":"","count":172,"signal":"Intermenstrual bleeding","source":"DrugCentral FAERS","actionTaken":"Reported 172 times (LLR=514)"},{"llr":467.714,"date":"","count":187,"signal":"Device leakage","source":"DrugCentral FAERS","actionTaken":"Reported 187 times (LLR=468)"},{"llr":382.163,"date":"","count":146,"signal":"Syringe issue","source":"DrugCentral FAERS","actionTaken":"Reported 146 times (LLR=382)"},{"llr":353.689,"date":"","count":163,"signal":"Heavy menstrual bleeding","source":"DrugCentral FAERS","actionTaken":"Reported 163 times (LLR=354)"},{"llr":290.52,"date":"","count":143,"signal":"Needle issue","source":"DrugCentral FAERS","actionTaken":"Reported 143 times (LLR=291)"},{"llr":274.24,"date":"","count":115,"signal":"Amenorrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 115 times (LLR=274)"},{"llr":270.114,"date":"","count":128,"signal":"Device occlusion","source":"DrugCentral FAERS","actionTaken":"Reported 128 times (LLR=270)"},{"llr":262.252,"date":"","count":167,"signal":"Device issue","source":"DrugCentral FAERS","actionTaken":"Reported 167 times (LLR=262)"},{"llr":260.215,"date":"","count":153,"signal":"Vaginal haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 153 times (LLR=260)"},{"llr":251.667,"date":"","count":188,"signal":"Breast cancer","source":"DrugCentral FAERS","actionTaken":"Reported 188 times (LLR=252)"},{"llr":228.724,"date":"","count":69,"signal":"Injection site abscess","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=229)"}],"drugInteractions":[{"url":"/drug/atazanavir","drug":"atazanavir","action":"Monitor closely","effect":"May interact with Atazanavir","source":"DrugCentral","drugSlug":"atazanavir"},{"url":"/drug/darunavir","drug":"darunavir","action":"Monitor closely","effect":"May interact with Darunavir","source":"DrugCentral","drugSlug":"darunavir"},{"url":"/drug/fosamprenavir","drug":"fosamprenavir","action":"Monitor closely","effect":"May interact with Fosamprenavir","source":"DrugCentral","drugSlug":"fosamprenavir"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Monitor closely","effect":"May interact with Nelfinavir Mesylate","source":"DrugCentral","drugSlug":"nelfinavir"},{"url":"/drug/rifabutin","drug":"rifabutin","action":"Monitor closely","effect":"May interact with Rifabutin","source":"DrugCentral","drugSlug":"rifabutin"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Avoid combination","effect":"May interact with Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/rifapentine","drug":"rifapentine","action":"Monitor closely","effect":"May interact with Rifapentine","source":"DrugCentral","drugSlug":"rifapentine"},{"url":"/drug/rufinamide","drug":"rufinamide","action":"Monitor closely","effect":"May interact with Rufinamide","source":"DrugCentral","drugSlug":"rufinamide"},{"url":"/drug/saquinavir","drug":"saquinavir","action":"Monitor closely","effect":"May interact with Saquinavir","source":"DrugCentral","drugSlug":"saquinavir"},{"url":"/drug/tipranavir","drug":"tipranavir","action":"Monitor closely","effect":"May interact with Tipranavir","source":"DrugCentral","drugSlug":"tipranavir"}],"commonSideEffects":[{"effect":"Abnormal uterine bleeding","drugRate":"reported","severity":"unknown"},{"effect":"Breast tenderness","drugRate":"reported","severity":"unknown"},{"effect":"Thromboembolic disorders","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Cholestatic jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Sensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Acne","drugRate":"reported","severity":"unknown"},{"effect":"Alopecia","drugRate":"reported","severity":"unknown"},{"effect":"Hirsutism","drugRate":"reported","severity":"unknown"},{"effect":"Neuro-ocular lesions","drugRate":"reported","severity":"unknown"},{"effect":"Mental depression","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Somnolence","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Nervousness","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Pyrexia","drugRate":"reported","severity":"unknown"},{"effect":"Edema/fluid retention","drugRate":"reported","severity":"unknown"},{"effect":"Fatigue","drugRate":"reported","severity":"unknown"},{"effect":"Decreased glucose tolerance","drugRate":"reported","severity":"unknown"},{"effect":"Breakthrough bleeding","drugRate":"reported","severity":"unknown"},{"effect":"Dysmenorrheal/pelvic pain","drugRate":"reported","severity":"unknown"},{"effect":"Increase in size of uterine leiomyomata","drugRate":"reported","severity":"unknown"},{"effect":"Vaginitis","drugRate":"reported","severity":"unknown"},{"effect":"Enlargement","drugRate":"reported","severity":"unknown"}],"contraindications":["Alcoholism","Anorexia nervosa","Asthma","Body fluid retention","Breast lump","Carcinoma of female breast","Cardiovascular event risk","Cerebrovascular accident","Cerebrovascular disease","Chloasma","Chorea","Deep venous thrombosis","Dementia","Depressive disorder","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Disorder of gallbladder","Epilepsy","Estrogen receptor positive tumor","Family history of malignant neoplasm of breast","Fibroadenosis of breast","Functional visual loss","Hepatic failure","Hepatic porphyria"],"specialPopulations":{"Pregnancy":"Pregnancy Category X. See WARNINGS section 6.","Geriatric use":"There have not been sufficient numbers of geriatric women involved in clinical studies utilizing MPA alone to determine whether those over 65 years of age differ from younger subjects in their response to MPA alone.. The Womens Health Initiative Studies. In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age. (See CLINICAL PHARMACOLOGY, Clinical Studies section).","Paediatric use":"Medroxyprogesterone Acetate Injectable Suspension, USP is not indicated before menarche. Use of Medroxyprogesterone Acetate Injectable Suspension, USP is associated with significant loss of BMD. This loss of BMD is of particular concern during adolescence and early adulthood, critical period of bone accretion. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity. It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP will result in a decrease in bone density in pediatric patients. It is unknown if use of Medroxyprogesterone Acetate Injectable Suspension, USP will result in a decrease in bone density in pediatric patients."}},"trials":[],"aliases":["Depo-Provera","medroxyprogesterone acetate","MPA","Provera","Provera Dosepak"],"company":"Pfizer","patents":[],"pricing":[],"allNames":"depo-provera","offLabel":[],"synonyms":["medroxyprogesterone","medroxyprogesterone acetate","medoxyprogesterone","medroxyprogesteron","depomedroxyprogesterone acetate","medroprogesterone acetate","hysron"],"timeline":[{"date":"1959-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PHARMACIA AND UPJOHN to Pfizer"},{"date":"1959-06-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"},{"date":"1992-10-29","type":"positive","source":"FDA Orange Book","milestone":"Depo-Provera approved — 150MG/ML"},{"date":"2004-12-17","type":"positive","source":"FDA Orange Book","milestone":"Depo-Subq Provera 104 approved — 104MG/0.65ML"}],"aiSummary":"Depo-Provera, also known as medroxyprogesterone, is a progestin medication originally developed by Pharmacia and Upjohn and currently owned by Pfizer. It targets the progesterone receptor and is used to treat a range of conditions including atrophic vaginitis, contraception, and endometrial hyperplasia. Depo-Provera is a small molecule medication that has been FDA-approved since 1959 and is available as a generic medication from multiple manufacturers. It has a bioavailability of 15% and is off-patent, meaning it is no longer protected by patents. Key safety considerations include potential side effects such as weight gain and changes in menstrual bleeding patterns.","approvals":[{"date":"1959-06-18","orphan":false,"company":"PHARMACIA AND UPJOHN","regulator":"FDA"}],"brandName":"Depo-Provera","ecosystem":[{"indication":"Atrophic vaginitis","otherDrugs":[{"name":"dienestrol","slug":"dienestrol","company":"Ortho Mcneil Pharm"},{"name":"drospirenone","slug":"drospirenone","company":"Exeltis Usa Inc"},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"},{"name":"estradiol acetate","slug":"estradiol-acetate","company":"Warner Ireland"}],"globalPrevalence":null},{"indication":"Contraception","otherDrugs":[{"name":"desogestrel","slug":"desogestrel","company":"Organon Usa Inc"},{"name":"dienogest","slug":"dienogest","company":""},{"name":"drospirenone","slug":"drospirenone","company":"Exeltis Usa Inc"},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Dysfunctional uterine bleeding","otherDrugs":[{"name":"norethindrone acetate","slug":"norethindrone-acetate","company":"Warner Chilcott Llc"},{"name":"norethisterone","slug":"norethisterone","company":"Ortho Mcneil Pharm"},{"name":"progesterone","slug":"progesterone","company":"Alza"}],"globalPrevalence":null},{"indication":"Endometrial Hyperplasia Prevention","otherDrugs":[{"name":"progesterone","slug":"progesterone","company":"Alza"}],"globalPrevalence":null},{"indication":"Endometrial carcinoma","otherDrugs":[{"name":"megestrol acetate","slug":"megestrol-acetate","company":"Bristol Myers Squibb"},{"name":"progesterone","slug":"progesterone","company":"Alza"}],"globalPrevalence":420000},{"indication":"Endometriosis","otherDrugs":[{"name":"danazol","slug":"danazol","company":""},{"name":"elagolix","slug":"elagolix","company":"Abbvie Inc "},{"name":"goserelin","slug":"goserelin","company":"Astrazeneca"},{"name":"leuprorelin","slug":"leuprorelin","company":""}],"globalPrevalence":null},{"indication":"Menopausal flushing","otherDrugs":[{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"conjugated estrogens","slug":"conjugated-estrogens","company":"Wyeth Pharms Inc"},{"name":"drospirenone","slug":"drospirenone","company":"Exeltis Usa Inc"},{"name":"estradiol","slug":"estradiol","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Postmenopausal osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"calcium citrate","slug":"calcium-citrate","company":""}],"globalPrevalence":200000000}],"mechanism":{"target":"Progesterone receptor","novelty":"Follow-on","targets":[{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"},{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"AKR1C3","source":"DrugCentral","target":"Aldo-keto reductase family 1 member C3","protein":"Aldo-keto reductase family 1 member C3"},{"gene":"SHBG","source":"DrugCentral","target":"Sex hormone-binding globulin","protein":"Sex hormone-binding globulin"},{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor beta"},{"gene":"NR3C2","source":"DrugCentral","target":"Mineralocorticoid receptor","protein":"Mineralocorticoid receptor"},{"gene":"AKR1C1","source":"DrugCentral","target":"Aldo-keto reductase family 1 member C1","protein":"Aldo-keto reductase family 1 member C1"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"}],"modality":"Small Molecule","drugClass":"Progestin","explanation":"Depo-subQ provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.Suppression of serum estradiol concentrations is likely to be responsible for the therapeutic effect on endometriosis-associated pain.","oneSentence":"Depo-Provera works by binding to the progesterone receptor in the body, which helps to regulate the menstrual cycle and prevent pregnancy.","technicalDetail":"Depo-Provera is a synthetic progestin that acts as an agonist at the progesterone receptor, leading to changes in gene expression and cellular function that ultimately result in the regulation of the menstrual cycle and prevention of pregnancy."},"commercial":{"launchDate":"1959","_launchSource":"DrugCentral (FDA 1959-06-18, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1659","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=medroxyprogesterone","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=medroxyprogesterone","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:32:36.436288","biosimilars":[],"competitors":[{"drugName":"ethinylestradiol","drugSlug":"ethinylestradiol","fdaApproval":"1943-06-25","relationship":"same-class"},{"drugName":"etynodiol","drugSlug":"etynodiol","fdaApproval":"1966-03-23","relationship":"same-class"},{"drugName":"megestrol acetate","drugSlug":"megestrol-acetate","fdaApproval":"1971-08-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"norethisterone","drugSlug":"norethisterone","fdaApproval":"1962-05-21","relationship":"same-class"},{"drugName":"levonorgestrel","drugSlug":"levonorgestrel","fdaApproval":"1968-04-16","patentExpiry":"Sep 7, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desogestrel","drugSlug":"desogestrel","fdaApproval":"1992-12-10","relationship":"same-class"},{"drugName":"norgestimate","drugSlug":"norgestimate","fdaApproval":"1989-12-29","relationship":"same-class"},{"drugName":"drospirenone","drugSlug":"drospirenone","fdaApproval":"2019-05-23","patentExpiry":"Jun 28, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"medroxyprogesterone","indications":{"approved":[{"name":"Atrophic vaginitis","source":"DrugCentral","snomedId":52441000,"regulator":"FDA"},{"name":"Contraception","source":"DrugCentral","snomedId":13197004,"regulator":"FDA"},{"name":"Dysfunctional uterine bleeding","source":"DrugCentral","snomedId":19155002,"regulator":"FDA"},{"name":"Endometrial Hyperplasia Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Endometrial carcinoma","source":"DrugCentral","snomedId":254878006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":420000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Endometriosis","source":"DrugCentral","snomedId":129103003,"regulator":"FDA"},{"name":"Menopausal flushing","source":"DrugCentral","snomedId":198436008,"regulator":"FDA"},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Prevention of premature ovulation during controlled ovarian stimulation","source":"DrugCentral","snomedId":732970000,"regulator":"FDA"},{"name":"Secondary malignant neoplasm of kidney","source":"DrugCentral","snomedId":94360002,"regulator":"FDA"},{"name":"Secondary physiologic amenorrhea","source":"DrugCentral","snomedId":86030004,"regulator":"FDA"}],"offLabel":[{"name":"Endogenous Estrogen Production Test","source":"DrugCentral","drugName":"medroxyprogesterone","evidenceCount":3,"evidenceLevel":"emerging"},{"name":"Polycystic ovaries","source":"DrugCentral","drugName":"medroxyprogesterone"},{"name":"Precocious puberty","source":"DrugCentral","drugName":"medroxyprogesterone","evidenceCount":110,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ethinylestradiol","brandName":"ethinylestradiol","genericName":"ethinylestradiol","approvalYear":"1943","relationship":"same-class"},{"drugId":"etynodiol","brandName":"etynodiol","genericName":"etynodiol","approvalYear":"1966","relationship":"same-class"},{"drugId":"megestrol-acetate","brandName":"megestrol acetate","genericName":"megestrol acetate","approvalYear":"1971","relationship":"same-class"},{"drugId":"norethisterone","brandName":"norethisterone","genericName":"norethisterone","approvalYear":"1962","relationship":"same-class"},{"drugId":"levonorgestrel","brandName":"levonorgestrel","genericName":"levonorgestrel","approvalYear":"1968","relationship":"same-class"},{"drugId":"desogestrel","brandName":"desogestrel","genericName":"desogestrel","approvalYear":"1992","relationship":"same-class"},{"drugId":"norgestimate","brandName":"norgestimate","genericName":"norgestimate","approvalYear":"1989","relationship":"same-class"},{"drugId":"drospirenone","brandName":"drospirenone","genericName":"drospirenone","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":["Endometrial Cancer","Endometrial Cancer Stage I","Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","Atypical Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Obesity & Overweight","Obesity (BMI > 35)"],"enrollment":82,"completionDate":"2026-12"},{"nctId":"NCT07488949","phase":"NA","title":"Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)","status":"RECRUITING","sponsor":"Fang Wang","startDate":"2024-04-09","conditions":["Chronic Endometritis"],"enrollment":1000,"completionDate":"2031-12-31"},{"nctId":"NCT07470632","phase":"NA","title":"Effect of Twin Hearts Meditation and Mandala Coloring on Exam Anxiety in Nursing Students","status":"COMPLETED","sponsor":"Near East University, Turkey","startDate":"2025-01-05","conditions":["Exam Anxiety"],"enrollment":100,"completionDate":"2025-01-20"},{"nctId":"NCT07319429","phase":"PHASE2,PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":["Endometrial Cancer","Fertility"],"enrollment":260,"completionDate":"2029-12-31"},{"nctId":"NCT06904274","phase":"PHASE3","title":"Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-11-24","conditions":["Endometrial Hyperplasia"],"enrollment":207,"completionDate":"2027-05-03"},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":["Malignant Neoplasm"],"enrollment":250,"completionDate":"2027-11-04"},{"nctId":"NCT06665997","phase":"PHASE4","title":"Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-06-26","conditions":["Sickle Cell Disease (SCD)","Vaso-Occlusive Pain Episode in Sickle Cell Disease"],"enrollment":65,"completionDate":"2027-10"},{"nctId":"NCT07032506","phase":"NA","title":"Intrauterine Stent Placement Following Hysteroscopic Septum Resection","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-03","conditions":["Intrauterine Adhesion"],"enrollment":320,"completionDate":"2031-12-31"},{"nctId":"NCT05726903","phase":"PHASE4","title":"Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-12-06","conditions":["Gender Dysphoria, Adolescent"],"enrollment":35,"completionDate":"2023-11-17"},{"nctId":"NCT05505435","phase":"PHASE4","title":"Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2022-08-01","conditions":["Contraception"],"enrollment":263,"completionDate":"2024-03-30"},{"nctId":"NCT06671548","phase":"PHASE3","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-01-15","conditions":["Heavy Menstrual Bleeding","Uterine Fibroids"],"enrollment":120,"completionDate":"2027-01-07"},{"nctId":"NCT07377734","phase":"PHASE2","title":"A Multicenter, Randomized, Open-Label, Controlled Clinical Trial of Intrauterine Injection of Recombinant Humanized Type III Collage in the Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia","status":"NOT_YET_RECRUITING","sponsor":"Wang Jianliu","startDate":"2026-01-30","conditions":["Atypical Endometrial Hyperplasia","Endometrial Cancer"],"enrollment":30,"completionDate":"2027-12-30"},{"nctId":"NCT03229057","phase":"PHASE3","title":"Comparing the Effects of Oral Contraceptive Pills Versus Metformin","status":"COMPLETED","sponsor":"Anuja Dokras","startDate":"2018-01-15","conditions":["PCOS"],"enrollment":240,"completionDate":"2024-07-15"},{"nctId":"NCT05452928","phase":"PHASE4","title":"Aciclovir Versus Placebo for HSV-2 Meningitis","status":"NOT_YET_RECRUITING","sponsor":"Jacob Bodilsen","startDate":"2026-06-01","conditions":["Herpes Simplex 2","Meningitis, Viral"],"enrollment":150,"completionDate":"2029-06-01"},{"nctId":"NCT07148999","phase":"PHASE1,PHASE2","title":"An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera","status":"RECRUITING","sponsor":"Urmila DIwekar","startDate":"2025-09-23","conditions":["Infertility (IVF Patients)"],"enrollment":200,"completionDate":"2026-02-15"},{"nctId":"NCT03689543","phase":"PHASE2","title":"Estrogen Receptor Beta and Mood","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2019-05-23","conditions":["Perimenopause-Related Depression"],"enrollment":74,"completionDate":"2024-09-09"},{"nctId":"NCT06816901","phase":"PHASE4","title":"Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2025-03-26","conditions":["Postpartum Contraception","Depot Medroxyprogesterone Acetate","Lactation","DMPA"],"enrollment":40,"completionDate":"2025-07-31"},{"nctId":"NCT07020429","phase":"NA","title":"Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-09-01","conditions":["Premature Ovarian Insufficiency"],"enrollment":276,"completionDate":"2030-07-30"},{"nctId":"NCT05651282","phase":"PHASE4","title":"Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2023-03-15","conditions":["Endometrium Cancer"],"enrollment":250,"completionDate":"2025-12"},{"nctId":"NCT07124195","phase":"PHASE3","title":"Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2025-08-10","conditions":["Malignant Solid Tumors","Moderate to High Emetogenic Chemotherapy (MEC/HEC) Drugs"],"enrollment":126,"completionDate":"2026-12-31"},{"nctId":"NCT04893798","phase":"PHASE1","title":"A Study Comparing Subcutaneous Injection of Sayana Press In the Upper Arm Versus Anterior Thigh and Abdomen","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-16","conditions":["Healthy"],"enrollment":67,"completionDate":"2025-07-24"},{"nctId":"NCT07098208","phase":"NA","title":"The Effect of Twin Heart Meditation on Exam Anxiety of Nursing Students","status":"COMPLETED","sponsor":"Near East University, Turkey","startDate":"2024-05-01","conditions":["Exam Anxiety","Meditation"],"enrollment":100,"completionDate":"2024-05-30"},{"nctId":"NCT06942377","phase":"PHASE2","title":"Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-15","conditions":["Endometrial Cancer"],"enrollment":140,"completionDate":"2027-12-01"},{"nctId":"NCT04997499","phase":"NA","title":"Adolescent Subcutaneous (SQ) Injection Video Validation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2021-09-29","conditions":["Medication Compliance","Contraception","Self-Evaluation"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT06914297","phase":"PHASE2","title":"TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-21","conditions":["Endometrial Cancer"],"enrollment":10,"completionDate":"2029-04-01"},{"nctId":"NCT06102863","phase":"PHASE2","title":"Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-04-01","conditions":["Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I"],"enrollment":38,"completionDate":"2025-09-01"},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":["HIV Infections","Contraception","Drug-drug Interaction"],"enrollment":700,"completionDate":"2026-03-31"},{"nctId":"NCT04669678","phase":"PHASE4","title":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-17","conditions":["HIV Infections","Contraception","Drug-drug Interaction"],"enrollment":110,"completionDate":"2024-02-05"},{"nctId":"NCT05247268","phase":"PHASE2","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-03-11","conditions":["Endometrial Neoplasm Malignant Stage I"],"enrollment":104,"completionDate":"2027-09-10"},{"nctId":"NCT05760144","phase":"EARLY_PHASE1","title":"Endometrial Biopsy in Progestin Contraceptive Users","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2023-07-01","conditions":["Contraception"],"enrollment":52,"completionDate":"2026-11"},{"nctId":"NCT06566430","phase":"NA","title":"PrEP My Way: a Hybrid Type 1 Clinical Effectiveness-implementation Trial to Promote PrEP Persistence Among Young Kenyan Women","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-03","conditions":["HIV/AIDS"],"enrollment":500,"completionDate":"2028-12-01"},{"nctId":"NCT03018366","phase":"PHASE2","title":"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-01-01","conditions":["Estrogen Deficiency","Cardiovascular Disease (CVD)","Functional Hypothalamic Amenorrhea","Endothelial Dysfunction"],"enrollment":29,"completionDate":"2023-02-01"},{"nctId":"NCT05056545","phase":"NA","title":"Postpartum Family Planning Program in Rwanda","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-08-01","conditions":["Family Planning"],"enrollment":26215,"completionDate":"2026-03-31"},{"nctId":"NCT02076217","phase":"","title":"Quick Start of Highly Effective Contraception","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-02","conditions":["IUD","Contraceptive Implant","Contraception","Birth Control","Emergency Contraception"],"enrollment":1030,"completionDate":"2026-01"},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":["Endometriosis Ovary"],"enrollment":80,"completionDate":"2024-11-19"},{"nctId":"NCT05255653","phase":"PHASE2,PHASE3","title":"Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2021-11-11","conditions":["Endometrial Cancer"],"enrollment":1615,"completionDate":"2031-01-01"},{"nctId":"NCT03660046","phase":"","title":"Contraceptive Hormones, Immunity, and Microbiome Evaluation","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-12-07","conditions":["Hormonal Contraception"],"enrollment":155,"completionDate":"2023-09-07"},{"nctId":"NCT03751800","phase":"","title":"A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-12","conditions":["Menorrhagia"],"enrollment":422,"completionDate":"2021-05-18"},{"nctId":"NCT05767086","phase":"NA","title":"Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-03-15","conditions":["Infertility"],"enrollment":297,"completionDate":"2024-09-30"},{"nctId":"NCT06637189","phase":"PHASE4","title":"Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.","status":"NOT_YET_RECRUITING","sponsor":"Ginefiv","startDate":"2024-10-15","conditions":["Stimulation in the Ovary","Embryo","Oocyte","Oocyte Retrieval","Fertilization in Vitro","Blastocyst","PGT-A"],"enrollment":144,"completionDate":"2025-12-31"},{"nctId":"NCT02228681","phase":"PHASE2","title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","status":"COMPLETED","sponsor":"GOG Foundation","startDate":"2015-05-21","conditions":["Advanced, Persistent, or Recurrent Endometrial Cancer"],"enrollment":74,"completionDate":"2024-08-22"},{"nctId":"NCT03154125","phase":"PHASE3","title":"Sayana® Press Extension Study","status":"COMPLETED","sponsor":"FHI 360","startDate":"2017-09-22","conditions":["Contraception"],"enrollment":750,"completionDate":"2020-11-18"},{"nctId":"NCT00830414","phase":"PHASE1","title":"Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-04","conditions":["Healthy"],"enrollment":124,"completionDate":"2002-09"},{"nctId":"NCT06549855","phase":"NA","title":"PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10","conditions":["Endometrial Cancer","Endometrioid Carcinoma","Mismatch Repair Deficiency"],"enrollment":10,"completionDate":"2029-10"},{"nctId":"NCT06468215","phase":"NA","title":"Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07","conditions":["Carcinoma, Endometrioid","Fertility Preservation"],"enrollment":16,"completionDate":"2028-10"},{"nctId":"NCT05675787","phase":"PHASE2","title":"Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01-06","conditions":["Atypical Endometrial Hyperplasia","Endometrial Carcinoma Stage I"],"enrollment":82,"completionDate":"2025-10-31"},{"nctId":"NCT06304220","phase":"NA","title":"Comparison of Two PPOS Models for Pituitary Suppression","status":"NOT_YET_RECRUITING","sponsor":"NextFertility","startDate":"2024-07","conditions":["Infertility, Female","Fertility Disorders"],"enrollment":210,"completionDate":"2024-12"},{"nctId":"NCT05280028","phase":"","title":"HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness","status":"RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2022-02-07","conditions":["Menopausal Syndrome"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT04408729","phase":"NA","title":"PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-08-10","conditions":["HIV/AIDS"],"enrollment":150,"completionDate":"2022-10-26"},{"nctId":"NCT03844633","phase":"PHASE4","title":"Postpartum Family Planning","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2019-03-21","conditions":["Delay in Time to Lactogenesis Stage II"],"enrollment":49,"completionDate":"2022-04-18"},{"nctId":"NCT04710017","phase":"NA","title":"Tranexamic Acid and Depot-Medroxyprogesterone Acetate for Perimenopausal Irregular Uterine Bleeding","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-02-01","conditions":["Uterine Bleeding"],"enrollment":110,"completionDate":"2022-05-01"},{"nctId":"NCT03559634","phase":"NA","title":"Contraception Initiation Feasibility in the Pediatric ED","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-05-20","conditions":["Contraception","Contraception Behavior"],"enrollment":55,"completionDate":"2023-01-30"},{"nctId":"NCT04989348","phase":"NA","title":"Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol","status":"COMPLETED","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2021-08-04","conditions":["IVF"],"enrollment":240,"completionDate":"2024-02-20"},{"nctId":"NCT04682353","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-12-14","conditions":["Contraception"],"enrollment":60,"completionDate":"2023-01-12"},{"nctId":"NCT02817464","phase":"PHASE1","title":"Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-10-26","conditions":["Pregnancy","Contraception"],"enrollment":12,"completionDate":"2018-12-03"},{"nctId":"NCT06067217","phase":"NA","title":"Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users","status":"UNKNOWN","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2023-09-30","conditions":["Abnormal Uterine Bleeding","Tranexamic Acid","Estrogen","Depot Medroxyprogesterone Acetate"],"enrollment":52,"completionDate":"2024-08-30"},{"nctId":"NCT00577122","phase":"PHASE2","title":"Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Indiana University","startDate":"2007-07","conditions":["Estrogen Receptor-negative Breast Cancer","Progesterone Receptor-negative Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":30,"completionDate":"2011-12"},{"nctId":"NCT04997811","phase":"PHASE2","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Prof. Janet Dunn","startDate":"2021-12-21","conditions":["Myelodysplastic Syndromes (MDS)"],"enrollment":120,"completionDate":"2025-06-30"},{"nctId":"NCT04414761","phase":"PHASE3","title":"Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-06-04","conditions":["IVF","GnRH Antagonist","PPOS"],"enrollment":784,"completionDate":"2022-10-10"},{"nctId":"NCT04814927","phase":"PHASE4","title":"Impact of Contraceptives on Cervico-Vaginal Mucosa","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2021-03-01","conditions":["Mucosal Inflammation","Contraceptive; Complications, Intrauterine"],"enrollment":112,"completionDate":"2022-12-15"},{"nctId":"NCT05973253","phase":"PHASE2,PHASE3","title":"Evaluation of Efficacy and Safety of Topical 1% Medroxyprogesterone in the Corneal Epithelium Healing After PRK","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2023-04-21","conditions":["Photorefractive Keratectomy"],"enrollment":74,"completionDate":"2023-07-06"},{"nctId":"NCT04910711","phase":"PHASE4","title":"Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV","status":"UNKNOWN","sponsor":"Botswana Harvard AIDS Institute Partnership","startDate":"2021-10-21","conditions":["Human Immunodeficiency Virus","Contraception","ART"],"enrollment":140,"completionDate":"2024-10-31"},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":["Endometrial Neoplasms","Endometrial Neoplasm Malignant","Endometrial Neoplasm Malignant Stage I","Carcinoma, Endometrioid","Fertility Preservation"],"enrollment":57,"completionDate":"2027-12-31"},{"nctId":"NCT00026286","phase":"PHASE3","title":"Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-11-28","conditions":["Breast Cancer","Hot Flashes","Menopausal Symptoms"],"enrollment":0,"completionDate":"2007-06-15"},{"nctId":"NCT03097120","phase":"PHASE3","title":"The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"1995-01","conditions":["Heart Disease"],"enrollment":309,"completionDate":"2001-01"},{"nctId":"NCT05859087","phase":"NA","title":"Family Planning Counseling for Women With Chronic Medical Conditions in an Inpatient Setting","status":"TERMINATED","sponsor":"Sutter Health","startDate":"2018-02-26","conditions":["Chronic Disease"],"enrollment":76,"completionDate":"2021-05-27"},{"nctId":"NCT04792749","phase":"PHASE3","title":"Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-06-01","conditions":["Endometrial Cancer Stage I"],"enrollment":77,"completionDate":"2024-03-31"},{"nctId":"NCT03916328","phase":"PHASE4","title":"BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study","status":"UNKNOWN","sponsor":"MU-JHU CARE","startDate":"2019-12-03","conditions":["Bone Loss"],"enrollment":330,"completionDate":"2024-03-31"},{"nctId":"NCT04423068","phase":"EARLY_PHASE1","title":"Inpatient Adolescent Contraception","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2020-12-10","conditions":["Pregnancy Related","Contraception","Contraceptive Usage","Contraception Behavior","Pregnancy"],"enrollment":25,"completionDate":"2023-04-04"},{"nctId":"NCT05742503","phase":"","title":"Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-30","conditions":["Progesterone","Contraceptive Methods"],"enrollment":80,"completionDate":"2022-03-30"},{"nctId":"NCT00653159","phase":"PHASE4","title":"Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2007-07","conditions":["Contraception"],"enrollment":23,"completionDate":"2008-12"},{"nctId":"NCT03675139","phase":"PHASE3","title":"MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia","status":"COMPLETED","sponsor":"Xiaojun Chen","startDate":"2019-02-26","conditions":["Endometrial Hyperplasia Without Atypia"],"enrollment":471,"completionDate":"2022-05-15"},{"nctId":"NCT04021017","phase":"PHASE1","title":"PRE-GAiN Bone Health Pilot Study","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01-21","conditions":["Anorexia Nervosa"],"enrollment":0,"completionDate":"2022-12-13"},{"nctId":"NCT05565573","phase":"PHASE2,PHASE3","title":"Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients","status":"UNKNOWN","sponsor":"Hua Li","startDate":"2022-11-01","conditions":["Fertility Sparing"],"enrollment":148,"completionDate":"2025-11-01"},{"nctId":"NCT05490524","phase":"NA","title":"Smart Living Homes: GATEKEEPER System With Patients With Cancer and Dementia in Cyprus","status":"UNKNOWN","sponsor":"Cyprus University of Technology","startDate":"2021-06-01","conditions":["Neoplasms","Cancer","Dementia"],"enrollment":300,"completionDate":"2023-03"},{"nctId":"NCT05491343","phase":"PHASE4","title":"Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2022-08","conditions":["Arteriovenous Malformations"],"enrollment":28,"completionDate":"2024-01"},{"nctId":"NCT02449161","phase":"PHASE3","title":"The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates","status":"TERMINATED","sponsor":"Guy Waddell","startDate":"2015-08","conditions":["Menorrhagia"],"enrollment":60,"completionDate":"2021-05"},{"nctId":"NCT01174225","phase":"PHASE4","title":"IUD Insertion Post First Trimester Abortion","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2010-09","conditions":["Contraception"],"enrollment":534,"completionDate":"2023-06-30"},{"nctId":"NCT02353247","phase":"NA","title":"Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant","status":"COMPLETED","sponsor":"Norton Healthcare","startDate":"2015-08","conditions":["Etonogestrel Contraceptive Implant, Bothersome Bleeding"],"enrollment":88,"completionDate":"2017-06-29"},{"nctId":"NCT03153709","phase":"","title":"Prospective Cohort Evaluating Pregnancy Rates, PK Interactions Among HIV+ Women on EFV Initiating LNG Implant or DMPA","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2017-08-17","conditions":["HIV Infections"],"enrollment":1382,"completionDate":"2021-12-10"},{"nctId":"NCT01822288","phase":"PHASE4","title":"The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2012-11-16","conditions":["Menopausal Syndromes"],"enrollment":125,"completionDate":"2021-08-26"},{"nctId":"NCT04887402","phase":"","title":"Parameters Declaring PCO Infertile Patients Either Sensitive or Resistant to Different Doses of Clomiphene Citrate.","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2021-01-01","conditions":["PCO","Induction of Ovulation","Clomiphene Citrate"],"enrollment":100,"completionDate":"2022-03"},{"nctId":"NCT00745108","phase":"PHASE3","title":"Tibolone Endometrium Study (Study 32972)(P06470)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-10-01","conditions":["Postmenopausal Women"],"enrollment":32,"completionDate":"2005-07-21"},{"nctId":"NCT03700658","phase":"PHASE1","title":"A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2019-01-15","conditions":["Contraception"],"enrollment":27,"completionDate":"2020-10-02"},{"nctId":"NCT02122198","phase":"NA","title":"Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09-08","conditions":["Cognitive Impairment","Executive Dysfunction","Endothelial Dysfunction","Cardiovascular Disease"],"enrollment":17,"completionDate":"2017-09-15"},{"nctId":"NCT01873170","phase":"","title":"Quantification of Immune Cells in Women Using Contraception (CHIC II)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2013-08","conditions":["HIV","Immune Cells (Mucosal and Systemic)","Contraception"],"enrollment":326,"completionDate":"2020-10"},{"nctId":"NCT00563576","phase":"NA","title":"Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-09","conditions":["Metrorrhagia"],"enrollment":71,"completionDate":"2009-02"},{"nctId":"NCT05138367","phase":"PHASE1","title":"Effects of UCA-PSCs in Women With POF","status":"COMPLETED","sponsor":"Li-jun Ding","startDate":"2018-12-01","conditions":["Premature Ovarian Failure"],"enrollment":20,"completionDate":"2019-12-01"},{"nctId":"NCT03018249","phase":"EARLY_PHASE1","title":"Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-11","conditions":["FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma","FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma"],"enrollment":50,"completionDate":"2021-03-12"},{"nctId":"NCT00088153","phase":"PHASE2,PHASE3","title":"Effects of Anorexia Nervosa on Bone Mass in Adolescents","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-07","conditions":["Anorexia Nervosa"],"enrollment":110,"completionDate":"2011-06"},{"nctId":"NCT03463252","phase":"PHASE2,PHASE3","title":"Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2018-04-01","conditions":["Endometrial Cancer","Atypical Endometrial Hyperplasia"],"enrollment":224,"completionDate":"2030-12-30"},{"nctId":"NCT03300960","phase":"PHASE3","title":"Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation","status":"COMPLETED","sponsor":"Instituto Valenciano de Infertilidad, IVI VALENCIA","startDate":"2017-10-20","conditions":["Infertility"],"enrollment":318,"completionDate":"2019-06-25"},{"nctId":"NCT00743574","phase":"NA","title":"Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)","status":"COMPLETED","sponsor":"Yale University","startDate":"2008-08","conditions":["Polycystic Ovarian Syndrome","Vitamin D Deficiency"],"enrollment":36,"completionDate":"2013-02"},{"nctId":"NCT04005391","phase":"NA","title":"Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-10-23","conditions":["Postpartum"],"enrollment":208,"completionDate":"2020-11-19"},{"nctId":"NCT03196492","phase":"","title":"Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-06-14","conditions":["Microbial Colonization"],"enrollment":234,"completionDate":"2021-06-14"},{"nctId":"NCT02943655","phase":"PHASE3","title":"Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-11-01","conditions":["Improve Quality of Life","Heavy Menstrual Bleeding"],"enrollment":240,"completionDate":"2021-02-10"},{"nctId":"NCT03255941","phase":"EARLY_PHASE1","title":"Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers","status":"COMPLETED","sponsor":"FHI 360","startDate":"2018-03-19","conditions":["Contraception"],"enrollment":460,"completionDate":"2018-07-23"},{"nctId":"NCT01641380","phase":"NA","title":"Meaningful Use of Technology to Improve Health Care Delivery","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":["Contraceptive Behavior"],"enrollment":100,"completionDate":"2017-09-01"},{"nctId":"NCT03398811","phase":"","title":"Abnormal Uterine Bleeding and Progestin-only Contraceptives","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-08-01","conditions":["Contraception"],"enrollment":390,"completionDate":"2020-11-01"},{"nctId":"NCT00997893","phase":"PHASE2","title":"Research Investigation of Soy and Estrogen","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2009-12","conditions":["Menopause","Hot Flashes"],"enrollment":96,"completionDate":"2015-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral, Subcutaneous, Intramuscular","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"MEDROXYPROGESTERONE ACETATE"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"Medroxyprogesterone Acetate"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"Medroxyprogesterone Acetate Injectable Suspension"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"medroxyprogesterone acetate"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"Depo-Provera"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"MEDROXYPROGESTERONE ACETATE"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"medroxyprogesterone acetate"},{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","productName":"medroxyprogesterone acetate"},{"form":"INJECTION, SUSPENSION","route":"SUBCUTANEOUS","productName":"Depo-SubQ Provera"},{"form":"INJECTION, SUSPENSION, EXTENDED RELEASE","route":"INTRAMUSCULAR","productName":"Medroxyprogesterone Acetate"},{"form":"TABLET","route":"ORAL","productName":"Medroxyprogesterone"},{"form":"TABLET","route":"ORAL","productName":"Medroxyprogesterone Acetate"},{"form":"TABLET","route":"ORAL","productName":"Provera"},{"form":"TABLET","route":"ORAL","productName":"medroxyprogesterone acetate"},{"form":"TABLET","route":"ORAL","productName":"MEDROXYPROGESTERONE ACETATE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147899","MMSL":"5032","NDDF":"001295","UNII":"HSU1C9YRES","VUID":"4019810","CHEBI":"CHEBI:6715","VANDF":"4017828","INN_ID":"853","RXNORM":"1000112","UMLSCUI":"C0025147","ChEMBL_ID":"CHEMBL717","KEGG_DRUG":"D00951","DRUGBANK_ID":"DB00603","PUBCHEM_CID":"10631","SNOMEDCT_US":"126112002","IUPHAR_LIGAND_ID":"2879","SECONDARY_CAS_RN":"520-85-4","MESH_DESCRIPTOR_UI":"D008525"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SUSPENSION","route":"INTRAMUSCULAR","company":"Pharmacia & Upjohn Company LLC","brandName":"Depo-Provera","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1959-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"},{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"15%"},"publicationCount":7417,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-03-31 10:30:03.782336+00","atcClassification":{"source":"DrugCentral","atcCode":"G03AA08","allCodes":["G03AA08","G03AA17","G03AC06","G03DA02","G03FA12","G03FB06","L02AB02"]},"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[{"date":"2026 Apr 28","pmid":"41881051","title":"Idiopathic Intracranial Hypertension Prevalence and Hormonal Contraception: A Meta-Analysis.","journal":"Neurology"},{"date":"2026 Mar 24","pmid":"41874764","title":"Effects of human chorionic gonadotropin on echotextural attributes of the original corpus luteum in Morada Nova ewes.","journal":"Tropical animal health and production"},{"date":"2026 Feb 4","pmid":"41856890","title":"Use of the injectable contraceptive medroxyprogesterone acetate in France in 2010-2023: A national descriptive study.","journal":"Therapie"},{"date":"2026 Mar 19","pmid":"41855532","title":"Effect of Medical Therapies for Endometriosis on Bone Health: A Systematic Review and Meta-analysis.","journal":"Obstetrics and gynecology"},{"date":"2026 Mar 12","pmid":"41825096","title":"Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis.","journal":"Gynecologic oncology"}],"combinationProducts":[{"brandName":"Prempro","ingredients":"conjugated estrogens + medroxyprogesterone"}],"companionDiagnostics":[],"genericManufacturers":16,"_genericFilersChecked":true,"genericManufacturerList":["Amarin Pharms","Amneal","Amphastar Pharms Inc","Barr","Cipla","Duramed Pharms Barr","Esi ","Eugia Pharma","Hikma","Hong Kong","Sandoz","Solvay","Sun Pharm","Teva Pharms Usa","Upsher Smith Labs","Xiromed"],"status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1959","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1959-06-18T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}